FINE-ONE预设分析:非奈利酮在1型糖尿病合并CKD中的急性eGFR变化
FINE-ONE预设分析纳入242例1型糖尿病合并慢性肾脏病(CKD)患者,随机接受非奈利酮或安慰剂治疗。非奈利酮组第1个月eGFR平均下降2.78 ml/min/1.73 m²,安慰剂校正后差异为-1.99 ml/min/1.73 m²(P=0.049)。急性eGFR下降耐受良好,无意外安全信号,且eGFR下降幅度越大与第3个月UACR降低越多相关。
要点
- 非奈利酮在1型糖尿病合并CKD患者中引起急性eGFR下降,但耐受良好。
- 急性eGFR变化在不同预设特征亚组间无差异。
- eGFR下降幅度越大与第3个月UACR降低越多相关。
核心结论
- 非奈利酮在1型糖尿病合并CKD患者中引起急性eGFR下降,但耐受良好,无意外安全信号。
- eGFR下降幅度越大与第3个月UACR降低越多相关。
研究设计与样本
- FINE-ONE预设分析,纳入242例1型糖尿病合并CKD成人患者。
- 患者eGFR ≥ 25至<90 ml/min/1.73 m²,UACR ≥ 200至<5000 mg/g,接受稳定RAS抑制。
- 随机1:1接受非奈利酮或安慰剂治疗。
主要发现
- 第1个月eGFR平均下降:非奈利酮组-2.78 ml/min/1.73 m²(95%CI -4.15至-1.40),安慰剂组-0.78 ml/min/1.73 m²(95%CI -2.22至0.66)。
- 治疗差异为-1.99 ml/min/1.73 m²(95%CI -3.97至-0.01,P=0.049)。
- 洗脱期安慰剂校正后eGFR在各组均升高。
- 急性eGFR变化在不同预设特征(基线eGFR、UACR、CVD病史、利尿剂使用)间无差异。
- eGFR下降幅度越大与第3个月UACR降低越多相关。
关键数值与推荐
- 主要结局为第1个月eGFR急性变化(eGFR dip)。
- eGFR下降亚组分为>0至≤10%下降、>10%下降和≥0%升高。
- 治疗中出现的不良事件(TEAE)发生率在各eGFR下降亚组间相当。
临床怎么用
- 非奈利酮用于1型糖尿病合并CKD患者时,急性eGFR下降可耐受,无需因轻度下降停药。
- eGFR下降幅度较大者可能预示UACR降低更多,但需监测肾功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The nonsteroidal mineralocorticoid receptor antagonist finerenone reduces urine albumin-to-creatinine ratio (UACR) in people with type 1 diabetes (T1D) and chronic kidney disease (CKD). This prespecified analysis evaluated acute changes in estimated glomerular filtration rate (eGFR) with finerenone and their impact on safety. METHODS: Adults with T1D and CKD (n = 242; eGFR ≥ 25-< 90 ml/min per 1.73 m2; UACR ≥ 200 to < 5000 mg/g) receiving stable renin-angiotensin system (RAS) inhibition were randomized 1:1 to finerenone or placebo. The primary outcome was acute change in eGFR (from baseline to month 1), termed "eGFR dip." Reversibility of eGFR change was assessed from end of the treatment (month 6) to follow-up (month 7). Change in eGFR was assessed across eGFR dip subgroups (eGFR > 0 to ≤ 10% decline, > 10% decline, and ≥ 0% increase) and prespecified characteristics (baseline eGFR, UACR, history of cardiovascular disease [CVD], and diuretic use). RESULTS: Mean acute eGFR decline at month 1 was greater with finerenone (-2.78 ml/min per 1.73 m2 [95% confidence interval [CI], -4.15 to -1.40]) versus placebo (-0.78 ml/min per 1.73 m2; [95% CI, -2.22 to 0.66]); treatment difference was -1.99 ml/min per 1.73 m2 (95% CI, -3.97 to -0.01 [P = 0.049]). Placebo-corrected eGFR increased during the washout period across the groups. Acute eGFR changes did not differ according to prespecified characteristics. The incidence of treatment-emergent adverse events (TEAEs) was comparable across eGFR dip subgroups in both the treatment groups. Greater declines in eGFR were associated with greater reductions in UACR at month 3. CONCLUSION: In people with T1D and CKD, finerenone induced an acute eGFR dip that was well tolerated without unexpected safety signals.
引用
- Cherney DZI, Yi TW, Heerspink HJL, et al. Acute eGFR Changes With Finerenone Examined in a Prespecified Analysis of FINE-ONE. Kidney Int Rep. 2026. PMID: 42927222. doi:10.1016/j.ekir.2026.107083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。